Filing Flows › GeneDx Holdings (WGS) › Diagnostic Test revenue
GeneDx Holdings (WGS) Diagnostic Test revenue by quarter
GeneDx Holdings' Diagnostic Test revenue was $112M in Q2 2026 (second quarter 2026), +11% from Q1 2026. Over the last 7 quarters it ranged from $85.7M (Q1 2025) to $117M (Q4 2025).
| Quarter | Diagnostic Test revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $112M | +11% | +12% |
| Q1 2026 | $101M | -14% | +18% |
| Q4 2025 | $117M | +3% | +24% |
| Q3 2025 | $114M | +14% | — |
| Q2 2025 | $99.5M | +16% | — |
| Q1 2025 | $85.7M | -9% | — |
| Q4 2024 | $94.2M | — | — |
Q2 2026 at a glance
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is GeneDx Holdings' Diagnostic Test revenue?
GeneDx Holdings' Diagnostic Test revenue was $112M in Q2 2026 (second quarter 2026), +11% from Q1 2026.
How has GeneDx Holdings' Diagnostic Test revenue changed?
Over the last 7 quarters it ranged from $85.7M (Q1 2025) to $117M (Q4 2025).